Geron Corporation (NASDAQ:GERN) Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET
Corporate Participants
Aron Feingold - VP of IR and Corporate Communications
John Scarlett - Chairman, President and Chief Executive Officer
Faye Feller - Executive Vice President and Chief Medical Officer
Anil Kapur - Executive Vice President, Corporate Strategy and Chief Commercial Officer
Michelle Robertson - Executive Vice President, Chief Financial Officer and Treasurer
Conference Call Participants
Tara Bancroft - TD Cowen
Gil Blum - Needham & Company
Joel Beatty - Baird
Kalpit Patel - B. Riley Securities
Operator
Thank you for standing by. My name is Jael and I will be your conference operator today. At this time I would like to welcome everyone to the Geron Q1 2024 Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks there will be a question-and-answer session. [Operator Instructions]
I would now like to turn the conference over to Aron Feingold. You may begin.
Aron Feingold
Good morning, everyone. Welcome to the Geron Corporation first quarter 2024 earnings conference call. I am Aron Feingold, Geron's Vice President of Investor Relations and Corporate Communications.
I'm joined today by several members of Geron's management team. Dr. John Scarlett, Chairman and Chief Executive Officer. Anil Kapur, Executive Vice President of Corporate Strategy and Chief Commercial Officer. Dr. Faye Seller, Executive Vice President and Chief Medical Officer. Michelle Robertson, Executive Vice President and Chief Financial Officer and Dr. Andrew Grethlein, Executive Vice President and Chief Operating Officer.
Before we begin please note that during the course of this presentation and question-and-answer session we will be making forward-looking statements regarding future events, performance, plans, expectations, and other projections including those relating to the therapeutic potential and potential regulatory approval of Imetelstat, anticipated clinical and commercial events and related timelines, the sufficiency of Geron's financial resources, and other statements that are not historical fact.
Actual events or results could differ materially. Therefore I refer you to the discussion under the heading risk factors in Geron's most recent periodic report filed with the SEC which identifies important factors that could cause actual results to differ materially from those contained in the forward-looking statement. Geron undertakes no duty or obligation to update our forward-looking statement.
With that I'll turn the call over to Chip. Chip?
John Scarlett
Thanks Aron. Good morning everyone. Thanks for joining us.
We're poised for a successful U.S. launch of Imetelstat for the treatment of transfusion-dependent anemia in patients with lower risk MDS. If approved we're deeply excited for the opportunity to bring patients what we believe is an important and differentiated medicine. With our PDUFA date on June 16th, we continue to work closely with the FDA as they complete the review of our new drug application.